Anew study presented at ENDO 2022, the annual meeting of the endocrine society in Atlanta, Georgia, has conducted a successful experiment to create a secure male contraceptive regime.
The drugs utilized in the experiment include DMAU and 11-MNTDC that are categorized as progestogenic androgens.
These medications work by lowering testosterone levels, which has a bearing on the reduction within the variety of sperm.
Conventionally, bringing down testosterone levels often leads to unpleasant negative effects. Nonetheless, nearly all of the lads within the clinical trial weren’t averse to the thought of continuous to take the drugs, reflecting that the negative effects were tolerable.
“Male contraception options are currently restricted to vasectomy and condoms, and are thus extremely limited as in comparison with female options,” said lead researcher Tamar Jacobsohn of the Contraceptive Development Program on the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
“Development of an efficient, reversible male contraceptive method will improve reproductive options for men and girls, have a significant impact on public health by decreasing unintended pregnancy, and permit men to have an increasingly lively role in family planning,” Jacobsohn added, explaining the importance of their experiment.
The experiment was devised in two Phase 1 clinical trials with 96 healthy male participants. The themes in each trial were prescribed either two or 4 oral pills containing the lively drug or a placebo. The participants were kept on this medication pattern for 28 days.
The outcomes were encouraging. It was found that testosterone levels reached below normal after seven days of being on the lively drug. The testosterone levels didn’t budge below the conventional range in subjects who took the placebo.
The study found that 75% of men who took the lively drug said they might be willing to make use of it in the long run, compared with 46.4 percent of those taking a placebo. Not surprisingly, men who were on the four-pill day by day dose (400 milligrams) exhibited lower levels of testosterone than those taking the two-pill day by day dose (200-milligram dose).
Also, no significant differences were observed between the 2 lively treatment groups when it comes to satisfaction with the drug or the openness to make use of it in the long run or recommend it to others.
“Men’s positive experiences in clinical trials and high rankings of acceptability for this male pill should serve to excite the general public about male contraception being potentially widely available in the approaching a long time,” Jacobsohn noted.